Active	Status	Sponsor type	Region	Phase	Filter
17 Active 8 Inactive 25 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GUERCI, Bruno
REALIST, NCT03648554: Researching an Effect of GLP-1 Agonist on Liver STeatosis	Not yet recruiting	4	93	Europe	dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring	Central Hospital, Nancy, France, Eli Lilly and Company	Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis	09/23	03/24
RADIANT, NCT05923827: Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults	Active, not recruiting	N/A	200	Europe	Omnipod 5 System	Insulet Corporation	Diabetes Mellitus, Type 1	08/24	08/25
SULTAN, Ariane
SURPASS-SWITCH, NCT05564039: A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide	Completed	4	282	Europe, US, RoW	Tirzepatide, LY3298176, Dulaglutide, LY2189265	Eli Lilly and Company	Type 2 Diabetes	07/24	08/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29